The Cost of Science: Knowledge and Ethics in the HIV Pre-Exposure Prophylaxis Trials

Journal of Bioethical Inquiry

Volumn 9, Issue 3, 2012, Pages 295-310

  Patton, Cindy ^a   Kim, Hye Jin ^a  

^a SIMON FRASER UNIVERSITY   (Canada)

Author keywords

Epidemiological methods; HIV AIDS; Public health; Queer health; Risk

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; DEVELOPING COUNTRY; EPIDEMIOLOGY; ETHICS; FEMALE; HARM REDUCTION; HETEROSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MALE HOMOSEXUALITY; RESEARCH ETHICS; RISK; WOMEN'S HEALTH;

ANTI-HIV AGENTS; DEVELOPING COUNTRIES; EPIDEMIOLOGIC METHODS; ETHICS, RESEARCH; FEMALE; HARM REDUCTION; HETEROSEXUALITY; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; MALE; RISK; WOMEN'S HEALTH;

EID: 84865539333     PISSN: 11767529     EISSN: 18724353     Source Type: Journal    
DOI: 10.1007/s11673-012-9383-x     Document Type: Article

References (31)

1. Adam, B. D. 2005. Constructing the neoliberal sexual actor: Responsibility and care of the self in the discourse of barebackers. Culture, Health & Sexuality 7(4): 333-346.
2. Adam, B. D. 2011. Epistemic fault lines in biomedical and social approaches to HIV prevention. Journal of the International AIDS Society 14(Supplement 2): S2.
3. AVAC. 2012. Leading AIDS advocates support FDA approval of pre-exposure prophylaxis (PrEP), a promising new HIV prevention method, for men and women. May 1. http://www. avac. org/ht/display/ReleaseDetails/i/43823/pid/212.
4. Avery, D. 2012. Study: Gay men with lots of partners should take daily pill to prevent HIV. Queerty, April 20. http://www. queerty. com/study-gay-men-with-lots-of-partners-should-take-daily-pill-to-prevent-hiv-20120420/.
5. Cahill, S. 2012. Policy focus: Pre-exposure prophylaxis for HIV prevention: Moving toward implementation. Boston: The Fenway Institute. http://www. fenwayhealth. org/site/DocServer/PolicyFocus_PrEP_v7_02. 21. 12. pdf?docID=9321.
6. Centers for Disease Control and Prevention. 2011. Interim guidance: Preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. Morbidity and Mortality Weekly Report 60(03): 65-68.
7. FHI. 2011. FHI statement on the FEM-PrEP HIV prevention study: FHI to initiate orderly closure of FEM-PrEP. April 18. http://www. fhi360. org/en/aboutfhi/media/releases/fem-prep_statement041811. htm.
8. Gilead Sciences. 2012. Gilead Sciences announces first quarter 2012 financial results. April 26. http://www. gilead. com/pr_1688123.
9. The Global Forum on MSM & HIV. 2011a. An analysis of major HIV donor investments targeting men who have sex with men and transgender people in low- and middle- income countries. Oakland, CA: MSMGF. http://www. msmgf. org/files/msmgf//Publications/GlobalFinancingAnalysis. pdf.
10. The Global Forum on MSM & HIV. 2011b. Access to HIV prevention services and attitudes about emerging strategies: A global survey of men who have sex with men (MSM) and their health care providers. Oakland, CA: MSMGF. http://www. msmgf. org/files/msmgf//Publications/MSMGFPrevStratSurveyReport. pdf.
11. Grant, R. M. 2010. Advocates' briefing on iPrEx PrEP trial results. Webinar hosted by AVAC, November 24. http://www. avac. org/ht/display/EventDetails/i/31406/TPL/MatDetails/pid/351 (webinar information and audio and presentation files), http://www. avac. org/ht/a/GetDocumentAction/i/32103 (presentation file).
12. Grant, R. M., J. R. Lama, P. L. Anderson, et al. 2010. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. The New England Journal of Medicine 363(27): 2587-2599.
13. iPrEX News. 2010a. iPrEX fact sheet: Rollover study and next steps. November 23. http://www. iprexnews. com/studyresults/pdfembargo/englishversion/iPrEx%20Fact%20Sheet%20Rollover%20Study%20and%20Next%20Steps%20PE. pdf.
14. iPrEX News. 2010b. iPrEX fact sheet: About the study. November 23. http://www. iprexnews. com/studyresults/pdfembargo/englishversion/iPrEx%20Fact%20Sheet%20About%20the%20iPrEx%20Study%20Final%20PE. pdf.
15. iPrEX Update. 2011. iPrEX study results are out. What next? Global iPrEX Update, no. 06-07. http://www. iprexnews. com/content/mediafiles/englishmedia/pdfs/Eng%20iPrEx_Update-6-7. pdf.
16. Juusola, J. L., M. L. Brandeau, D. K. Owens, and E. Bendavid. 2012. The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men. Annals of Internal Medicine 156(8): 541-550.
17. Kreiss, J., E. Ngugi, K. Holmes, et al. 1992. Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. Journal of the American Medical Association 268(4): 477-482.
18. Mayer, K. 2012. Next PrEP: The next chapter in PrEP. Making Life healthier, January. http://www. fenwayhealth. org/site/News2?page=NewsArticle&id=7832.
19. McNeil Jr., D. G. 2010. Daily pill greatly lowers AIDS risk, study finds. The New York Times, November 23. http://www. nytimes. com/2010/11/24/health/research/24aids. html.
20. MedlinePlus. 2010. Tenofovir. http://www. nlm. nih. gov/medlineplus/druginfo/meds/a602018. html.
21. Microbicide Trials Network. 2011. MTN statement on decision to discontinue use of oral tenofovir tablets in VOICE, a major HIV prevention study in women. September 28. http://www. mtnstopshiv. org/node/3619.
22. Mills, E., B. Rachlis, P. Wu, E. Wong, K. Wilson, and S. Singh. 2005. Media reporting of tenofovir trials in Cambodia and Cameroon. BMC International Health and Human Rights 5: 6. doi: 10. 1186/1472-698X-5-6.
23. Mujuriga, A., J. M. Baeten, D. Donnell, et al. 2002. Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention. PLoS One 6(10): e25828. doi: 10. 1371/journal. pone. 0025828.
24. National Institute of Allergy and Infectious Diseases. 2010. Questions and Answers: The iPrEX study: Pre-exposure prophylaxis as HIV prevention among men who have sex with men. November 23. http://www. niaid. nih. gov/news/QA/Pages/iPrExQA. aspx.
25. Open Letter. 2011. Open letter to the FDA and Gilead Sciences: On the timing of the review and approval of pre-exposure prophylaxis for HIV prevention. http://fenwayfocus. org/2011/10/open-letter-to-the-fda-and-gilead-sciences-dont-hold-up-prep/.
26. Paltiel, D., K. A. Freedberg, C. A. Scott, et al. 2009. HIV Preexposure prophylaxis in the United States: Impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clinical Infectious Diseases 48(6): 806-815.
27. Paxton, L. A., T. Hope, and H. W. Jaffe. 2007. Pre-exposure prophylaxis for HIV infection: What if it works? The Lancet 370(9581): 89-93.
28. Petryna, A. 2009. When experiments travel: Clinical trials and the global search for human subjects. Princeton and Oxford: Princeton University Press.
29. QueerPlanet. 2012. Gay men with many sex partners should take daily pill to ward off HIV: cost. April 18. http://queerplanet. net/2012/04/18/gay-men-with-many-sex-partners-should-take-daily-pill-to-ward-off-hiv-cost/.
30. Shelton, J. D. 2011. HIV/AIDS. ARVs as HIV prevention: A tough road to wide impact. Science 334(6063): 1645-1646.
31. van Damme, L., G. Ramjee, M. Alary, et al. 2002. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: A randomised controlled trial. The Lancet 360(9338): 971-977.